Medicenna Announces Nasdaq Delisting and Cutback of Management Team
October 27, 2023 07:55 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors
October 25, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
New data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting on November 4, 2023 Company expects to...
Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)
October 24, 2023 07:15 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
October 10, 2023 07:07 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy
October 03, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
MDNA223 is a bifunctional Superkine designed to activate cancer-killing immune cells via the IL-2 receptor while simultaneously preventing their exhaustion by blocking PD-1 signallingMDNA223...
Medicenna Announces Results of Annual and Special Meeting of Shareholders
September 28, 2023 17:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage immuno-oncology company focused on the...
Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy
September 28, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
August 28, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella’s appointment...
Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management
August 14, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent.Brent Meadows, MBA, joins as Chief Business Officer (CBO), bringing over 25 years of...